Meena B Bansal, MD

Dr. Bansal has been on faculty at Mount Sinai since 2001. In addition to maintaining an NIH funded research program focused on molecular mechanism of liver fibrosis with seminal contributions to our understanding of liver fibrosis in people living with HIV,  Dr. Bansal held many different leadership roles at Mount Sinai, including Transplant Hepatology Fellowship Director, Director of Translational Research, Medical Director of Hospital-Based Clinics, Chief Medical Officer of Mount Sinai Care, LLC, Deputy Chief Medical Officer for Mount Sinai Health Partners, and Vice President of Population Health for Quality and Efficiency. In these latter roles, she helped generate increased quality dollars in value-based contracts, created Mount Sinai’s first ambulatory pharmacy program, addressed broad population health needs, and gained knowledge about payer relations in an ever-changing health care landscape.

From a Clinical Perspective, she is currently focused on the treatment and management for those with Metabolic Dysfunction Associated Steatohepatitis (MASH), formerly known as Non-alcoholic steatohepatits (NASH). She has served as the principal investigator for numerous clinical trials for MASH/NASH and has been greatly involved with bringing new therapeutics to patients.

At the international/national levels, she held the position of Secretary for the American Association for the Study of Liver and currently serves as the Director of thenewly formed MASLD/MASH (NAFLD/NASH) Center of Excellence at Mount Sinai.

Most recently, in January 2024, Dr. Bansal was named System Chief, Division of Liver Diseases for the Mount Sinai Health System.